The Trump Administration has announced new policy measures it hopes will increase access to Anti-Obesity Medications (AOMs), an unexpected move given the Administration’s earlier reversal of a Biden-era rule providing Medicare coverage of AOMs. Through new pricing agreements with Eli Lilly and Novo Nordisk, the Administration will reduce the cost of GLP1 weight-loss drugs, enabling Medicare and Medicaid to cover these medications. Beginning mid-2026, AOMs will be available to eligible Medicare beneficiaries at a monthly copay of $50, with a government-set price of $245 for both Medicare and State Medicaid programs. The agreement also includes a commitment from both manufacturers to provide Most Favored Nation (MFN) pricing on all future products and to extend MFN pricing access to every State Medicaid program nationwide.